Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 5.2% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care (TNDM) is a company that specializes in diabetes management solutions, such as insulin pumps and related technologies. The diabetes care products market is competitive and focused on innovation to enhance patient outcomes.

Why is Tandem Diabetes Care, Inc. going down?

TNDM stock is down 5.2% on Apr 21, 2026 15:01

• Tandem Diabetes Care (TNDM) stock saw a decrease, despite TD Cowen boosting its price target to $28 and maintaining a Buy rating. The decline could be linked to investors taking profits after a period of price appreciation.
• The Chief Operating Officer of the company exercised restricted stock units (RSUs), with some shares held back for taxes. This action may have added selling pressure on the stock as more shares became available in the market.
• Although there was excitement surrounding the upcoming launch of the Mobi Tubeless product and a new pay-as-you-go program, these factors might not have been enough to counterbalance the short-term selling pressures that led to the observed decrease in stock value.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Tandem Diabetes stock price target raised to $28 by TD Cowen

TD Cowen increased its price target for Tandem Diabetes Care (NASDAQ:TNDM) to $28 from $25, maintaining a Buy rating. This adjustment follows the company's new pay-as-you-go program and the anticipated launch of the Mobi Tubeless product, which analysts believe will drive significant revenue growth despite initial distribution model transition headwinds. The firm projects strong gross margins and EBITDA at scale after the two-to-three year transition period.

https://www.investing.com/news/analyst-ratings/tandem-diabetes-stock-price-target-raised-to-28-by-td-cowen-93CH-4623737

TD Cowen Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $28

TD Cowen has reiterated its Buy rating for Tandem Diabetes Care (TNDM.US) and increased its target price to $28. This update reflects the firm's continued confidence in the company's performance and future outlook.

https://www.moomoo.com/news/post/68513382/td-cowen-maintains-tandem-diabetes-care-tndmus-with-buy-rating

Tandem Diabetes (TNDM) COO exercises RSUs; shares withheld for taxes

Tandem Diabetes Care EVP & Chief Operating Officer Jean-Claude Kyrillos exercised 3,636 restricted stock units (RSUs) on April 15, 2026, converting them into common shares. To cover tax withholding, 1,926 common shares were withheld by the company at $20.66 per share, with no shares sold on the open market. Following these transactions, Kyrillos directly holds 25,772 common shares and 18,181 RSUs.

https://www.stocktitan.net/sec-filings/TNDM/form-4-tandem-diabetes-care-inc-insider-trading-activity-499160d291c1.html

Trending Today

Brent Crude Oil ($BRENT) Commodity Forecast: Up 5.0% Today

Crude Oil ($CRUDE) Commodity Forecast: Up 5.3% Today

Heating Oil ($HEATOIL) Commodity Forecast: Up 5.0% Today

Gasoline ($GASOLINE) Commodity Forecast: Up 7.3% Today

The Boeing Company ($BA) Stock Forecast: Up 5.2% Today

Masco Corporation ($MAS) Stock Forecast: Up 10.5% Today

TE Connectivity Ltd. New Switzerland Registered Shares ($TEL) Stock Forecast: Down 9.3% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.3% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Up 6.2% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 5.3% Today

Tandem Diabetes Care, Inc. Price History

21.03.2026 - TNDM Stock was down 5.2%

• Tandem Diabetes Care (TNDM) stock saw a decrease, despite TD Cowen boosting its price target to $28 and maintaining a Buy rating. The decline could be linked to investors taking profits after a period of price appreciation.
• The Chief Operating Officer of the company exercised restricted stock units (RSUs), with some shares held back for taxes. This action may have added selling pressure on the stock as more shares became available in the market.
• Although there was excitement surrounding the upcoming launch of the Mobi Tubeless product and a new pay-as-you-go program, these factors might not have been enough to counterbalance the short-term selling pressures that led to the observed decrease in stock value.

19.02.2026 - TNDM Stock was up 5.6%

• Despite reporting a Q4 loss, Tandem Diabetes Care exceeded revenue expectations, showcasing strong growth in its top line.
• The exercise of Restricted Stock Units by company executives and insiders selling shares may have initially caused some downward pressure on the stock price.
• A stock upgrade by Piper Sandler and a positive market outlook contributed to the bullish movement, reflecting investor confidence in the company's future prospects.
• The detailed financial overview and competitor comparison provided insights into Tandem Diabetes Care's revenue sources and financial health, potentially reassuring investors and contributing to the positive market sentiment.

17.02.2026 - TNDM Stock was up 7.3%

• The positive movement in TNDM stock today could be linked to the company's new product releases, such as insulin pump software and the introduction of Tandem Mobi.
• Despite industry competition and economic challenges, TNDM's solid financial position and emphasis on advanced solutions appear to have appealed to investors.
• The recent net loss in the fourth quarter of 2025 might have been overlooked due to the perceived long-term growth prospects of Tandem Diabetes, contributing to the optimistic sentiment in the market today.

30.02.2026 - TNDM Stock was down 5.4%

• An amended Schedule 13G/A filing by The Vanguard Group, indicating 0 shares beneficially owned, could have triggered uncertainty among investors.
• An ongoing investigation by the Portnoy Law Firm regarding potential securities fraud linked to malfunctions in Tandem's insulin pumps likely impacted the company's product reliability and financial transparency, resulting in a stock price decline.
• Despite exceeding Q4 earnings estimates, a neutral recommendation from Mizuho and a consensus "Hold" rating from analysts may have contributed to the subdued sentiment surrounding Tandem Diabetes Care, aligning with the bearish market movement.
• The combination of the investigation, neutral recommendations, and the lack of clear bullish sentiments likely intensified selling pressure on TNDM shares, leading to the observable significant bearish movement.

14.03.2026 - TNDM Stock was up 6.0%

• The surge in TNDM stock price could be attributed to the company being perceived as undervalued, with a GF Score of 74 indicating above-average potential for long-term returns.
• Maintaining a "Hold" rating and a target price of $22 might have provided investors with confidence in the current valuation of the stock.
• Positive sentiment from an AI analysis suggesting specific trading strategies and key support levels could have attracted more investors to TNDM.
• The overall bullish trend in the diabetes care market, with projected growth and technological advancements, might have positively impacted TNDM's stock price as it positions itself as a key player in the industry.

08.03.2026 - TNDM Stock was up 5.6%

• The bullish movement in Tandem Diabetes Care's stock today could be attributed to the company's request for shareholder approval for an increase in shares to its Long-Term Incentive Plan, signaling confidence in its future growth prospects.
• The projected growth in the Smart Insulin Management Devices Market, where Tandem Diabetes Care is a key player, could have also positively impacted investor sentiment and contributed to the stock's rise.
• Despite a reduction in stake by a notable financial institution, the overall market seems optimistic about Tandem Diabetes Care's performance, especially with the upcoming announcement of its first-quarter 2026 financial results, which investors are eagerly anticipating for insights into the company's trajectory.

13.03.2026 - TNDM Stock was up 5.5%

• TNDM stock started positively with a 5.69% gain, surpassing the S&P 500 performance.
• The optimistic outlook is supported by AI models suggesting favorable short-term sentiment and specific trading recommendations for large investors.
• In spite of a reduced price target by Goldman Sachs, TNDM stock remained strong, demonstrating robust confidence from investors in the company's potential for growth.
• Anticipated market expansion in diabetes care market by 2030, along with TNDM's innovative product range, likely influenced the market positively as investors foresee rising demand for diabetes care solutions.

24.02.2026 - TNDM Stock was down 6.4%

• Despite recent positive developments, Tandem Diabetes Care (TNDM) saw a decrease in stock value.
• Investors may have been discouraged by the company's lack of profitability despite exceeding earnings and revenue projections, prompting some to realize profits.
• While analysts praised TNDM's pay-as-you-go pharmacy model, this alone may not have calmed market worries or profit expectations.
• The decline in stock value could be influenced by broader market trends or factors specific to Tandem Diabetes Care's industry performance.

27.02.2026 - TNDM Stock was down 6.9%

• Tandem Diabetes Care, Inc. experienced a bearish movement due to a significant 19.9% stock price drop following the disclosure of a malfunction in its insulin pumps.
• An investigation regarding potential securities fraud added further uncertainty and negative sentiment towards the company.
• The malfunction in the insulin pumps, which could lead to serious health complications for users, likely raised concerns among investors about the company's product safety and reliability.
• The market reacted strongly to the news, reflecting the importance of transparency and reliability in the healthcare technology sector.

07.03.2026 - TNDM Stock was up 6.2%

• Significant divestment of Tandem Diabetes Care shares by JPMorgan Chase & Co. initially raised investor concerns, but the market sentiment later turned positive.
• Despite Tandem Diabetes Care's ongoing lack of profitability, the stock witnessed a bullish trend leading up to the upcoming Q1 2026 financial results announcement.
• A mix of analyst opinions, resulting in a "Hold" consensus rating, and upgrades from some firms, likely influenced the positive investor sentiment as the company's potential was reassessed.
• Market enthusiasm and confidence in Tandem Diabetes Care's future performance, bolstered by beating earnings estimates for the quarter, drove the stock to a significant bullish movement.

07.03.2026 - TNDM Stock was down 5.8%

• The Smart Insulin Management Devices Market is projected to grow substantially by 2033, indicating a positive industry outlook. However, Tandem Diabetes Care's stock experienced a bearish trend.
• A reduction of 36.1% in Tandem Diabetes Care's stake by JPMorgan Chase & Co. could have contributed to the negative sentiment surrounding the stock.
• Despite beating earnings estimates, Tandem Diabetes Care remains unprofitable, leading to mixed analyst sentiment and a "Hold" consensus rating.
• The upcoming announcement of Tandem Diabetes Care's Q1 2026 results may have investors cautious, waiting for insights into the company's performance and future prospects before making investment decisions.

16.03.2026 - TNDM Stock was down 6.1%

• TNDM shares rose by 4.8% to $20.10, despite being undervalued, potentially prompting profit-taking by investors and contributing to the bearish trend.
• Mizuho Securities has maintained a "Hold" rating with a target price of $22, suggesting a neutral outlook that may not be driving significant positive momentum for the stock.
• Institutional trading strategies utilizing AI models could have resulted in selling pressure if recommended short positions were achieved.
• Anticipated growth in the diabetes care market until 2030 may have redirected investor attention towards other industry leaders, negatively impacting TNDM's stock performance in the short term.